Search

everythinglearnresearchcommunity

for

Search:↓

IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.

Hair loss treatment caused more hair loss in a man.

Inflammation linked to the immune response may play a role in causing various types of hair loss.

Intradermal testing can better detect corticosteroid allergies than patch testing.

Inflammation may play a role in causing androgenetic alopecia.

Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.

Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.

Serum granulysin levels can indicate the activity and prognosis of alopecia areata.

Two men experienced hair regrowth while being treated with immune globulin for other health issues, but there were also side effects.

Ruxolitinib helped a patient with alopecia areata regrow hair.

The conclusion is that a new method could improve the identification of autoimmune targets in alopecia areata, despite some limitations.

Patients with alopecia areata and eosinophilia have more nail issues and severe hair loss.

A new AIRE gene mutation causes rare autoimmune symptoms in a Lebanese boy.

ALEP is a drug-triggered skin reaction with pustules that clears up in a week after stopping the drug.

ILC1-like cells can independently cause alopecia areata by affecting hair follicles.

Agaricus bisporus derived β-Glucan could be an effective cervical cancer treatment with antimicrobial and antioxidant properties.

Early stage bald spots are linked to skin inflammation and damage to the upper part of the hair follicle.

A man with both skin lesions and lung cancer improved quickly with chemotherapy, suggesting the skin condition might be a reaction to immune system injury.

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

Intralesional corticosteroids effectively treat localized alopecia areata, often sparing white hairs.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.

Both atopy and eosinophilia are linked to more severe hair loss in people with alopecia areata.

Three children with nasal fungal infections were successfully treated with potassium iodide and sometimes itraconazole.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.